Engineered immune cells take on lupus in early trial

NCT ID NCT07339332

Recruiting now Disease control Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study is testing a new type of immunotherapy called universal CAR-T cells in 12 people with moderate to severe lupus that hasn't responded to standard treatments. The cells are designed to target and destroy faulty immune cells driving the disease. The main goals are to check safety and find the right dose, while also seeing if it can improve lupus symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: universal CD19/20 CAR-T cells (CT1195E)
What this could lead to: If it works, this could point toward a new treatment option for people with hard-to-treat lupus, potentially reducing disease activity without lifelong medication.
What could go wrong: This is a very early, small trial (12 people) focused on safety. CAR-T therapy can cause severe side effects like cytokine release syndrome, and it is unknown if it will work for lupus or how long effects might last.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Contacts and locations

Locations

Wuhan Union Hospita
RECRUITING

Wuhan, Hubei, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.